Skip to main content

Table 2 Toxicity during the course of chemoradiation

From: Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study

 

Grade 1

Grade 2

Grade 3

 

n

%

n

%

n

%

Diarrhea

15

19.2%

11

14.1%

8

10.3%

Hematologic

13

16.7%

3

3.8%

3

3.8%

Fatigue

10

12.8%

5

6.4%

3

3.8%

Radiation dermatitis

20

25.6%

16

20.5%

14

17.9%

Neurosensory

3

3.8%

1

1.3%

0

0.0%

Hand-foot syndrome

0

0.0%

1

1.3%

0

0.0%